Pfizer and Other Drug Makers Report Higher Profits [New York Times]
Summary: Pharmaceutical companies Pfizer, Eli Lilly, Novartis and Wyeth all reported profit gains yesterday, driven in part by a rise in prescriptions written in the U.S. as a result of the new Medicare Part D drug insurance program. Pfizer did caution, however, that it expects flat revenues for the next two years as patents expire on Zoloft, a popular antidepressant, and Norvasc, a high blood pressure drug. Pfizer is also delaying distribution of Exubera, its highly touted, FDA-approved inhaled insulin, until January over concerns about its effect on the lungs. Still, Pfizer expects EPS to grow 7-9% in both 2007 and 2008 through cost-cutting and share buybacks. Novartis AG reported a 12% Q3 net profit rise and Eli Lilly a 10% jump.
Related links: With Pfizer Bigger is Better • Merck Wins FDA Approval for New Type-2 Diabetes Drug • Drug Companies Report Solid 3Q Results [Newsday]
Potentially impacted stocks and ETFs: Pfizer Inc. (PFE), Merck & Co. (MRK), Eli Lilly & Co. (LLY), Novartis AG (NVS), Wyeth (WYE) • First Trust Morningstar Dividend Leaders Index Fund (FDL), iShares Dow Jones U.S. Pharmaceuticals Index Fund (IHE), WisdomTree Trust WisdomTree HighYielding Equity (DHS)
Seeking Alpha is not affiliated with New York Times.